- Bufalin
-
- $48.00
-
2026-07-14
- CAS:465-21-4
- Purity: 99.80%
- Supply Ability: 10g
- Bufalin
-
-
2023-02-24
- CAS:465-21-4
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
- Bufalin
-
- $15.00
-
2021-07-02
- CAS:465-21-4
- Min. Order: 1KG
- Purity: 99%+ HPLC
|
| Product Name: | Bufalin | | Synonyms: | 22-dienolide,3,14-dihydroxy-,(3-beta,5-beta)-bufa-2;Bufalin, 98%, from bufonis venenum;Bufalin, >=98%;22-dienolide,3-beta,14-dihydroxy-5-beta-bufa-2;BUFA-20,22-DIENOLIDE, 3,14-DIHYDROXY-, (3B,5B)-;BUFALIN;(3BETA,5BETA)-3,14-DIHYDROXYBUFA-20,22-DIENOLIDE;3-BETA-14-DIHYDROXY-5-BETA-BUFA-20,22-DIENOLIDE | | CAS: | 465-21-4 | | MF: | C24H34O4 | | MW: | 386.53 | | EINECS: | | | Product Categories: | Inhibitors;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;chemical reagent;pharmaceutical intermediate;phytochemical;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids | | Mol File: | 465-21-4.mol |  |
| | Bufalin Chemical Properties |
| Melting point | 242-243° | | alpha | D -20° | | Boiling point | 556.6±50.0 °C(Predicted) | | density | 1.226±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO:36.0(Max Conc. mg/mL);93.14(Max Conc. mM)
DMF:25.0(Max Conc. mg/mL);64.68(Max Conc. mM)
Ethanol:27.5(Max Conc. mg/mL);71.15(Max Conc. mM)
Ethanol:PBS (pH 7.2) (1:2):0.3(Max Conc. mg/mL);0.78(Max Conc. mM) | | pka | 15.01±0.70(Predicted) | | form | White to off-white solid | | color | White to off-white | | Major Application | food and beverages | | InChIKey | QEEBRPGZBVVINN-ONGIWDLKSA-N | | SMILES | O[C@]12CC[C@H](C3=COC(C=C3)=O)[C@]1(CC[C@]1([H])[C@]3(CC[C@@H](C[C@@]3([H])CC[C@@]21[H])O)C)C |
| Hazard Codes | T+ | | Risk Statements | 28 | | Safety Statements | 28-36/37-45 | | RIDADR | UN 3462 6.1/PG 2 | | WGK Germany | 3 | | RTECS | EI2962500 | | HazardClass | 6.1(a) | | PackingGroup | II | | HS Code | 29322090 | | Storage Class | 6.1A - Combustible acute toxic Cat. 1 and 2
very toxic hazardous materials | | Hazard Classifications | Acute Tox. 2 Oral |
| | Bufalin Usage And Synthesis |
| Pharmacological effects | Bufalin is one of the main components of dried secretions of toad which is Bufo , Bufalin has a strong surface anesthetic effect, and it has a long-lasting effect in rabbit cornea and human tongue tests which is stronger than cocaine, about 90 times of cocaine. intravenous fluid Toad (0.05mg/kg) on Anesthetized rabbits , anesthetized rabbits can be caused breathing excitement, cat can also be caused breathe excitement . Its effect is stronger than nikethamide , pentylenetetrazol, lobeline, etc. and it can antagonize morphine respiratory depression. Respiratory stimulant order: Bufalin>Resibufogenin= Cinobufagin =cinobufotaline> Japanese toad toxins.
Bufalin low concentrations (10-4) promote release of presynaptic acetylcholine on rat diaphragm , while high concentrations promote first then inhibit, and partly antagonize the neuromuscular blocking effects of Mg2 +,but no inhibition on choline esterase.
The above information is edited by the Chemicalbook of Tian Ye.
| | Category | Toxic substances
| | Toxicity grading | Highly toxic
| | Acute toxicity | Intraperitoneal-mouse LD50: 2.2 mg/kg
| | Flammability and hazard characteristics | Flammable,the fire produces acrid smoke .
| | Storage Characteristics | Ventilated, low-temperature ,dry storeroom,separate from food raw materials .
| | Extinguishing agent | Water, carbon dioxide, dry powder,sandy soil
| | Chemical Properties | It comes from the dried secretions of toads such as the Chinese giant toad Bufo bufo gargarizans Cantor or the black-spotted toad Bufo melanostictus Schneider. | | Uses | Bufalin has been used:
- to test its effect on invasion and activation of nuclear factor kappa- B (NF-κB) cells and tumor necrosis factor-α (TNF-α) stimulated rheumatoid arthritis fibroblast-like synoviocytes (RAFLSs)
- as a nuclear receptor coactivator 3 (NCOA3) inhibitor in chondrocytes
- to test its anti-metastasis effect in lung cancer cells (NCI-H460) resistant to gefitinib
| | Uses | A bufadienolide derivative, cardiac steroid, a component of bufadienolides present in the traditional Chinese medicine Chan'su, used therapeutically for the treatment of heart disease, also has been reported as a protective factor in many tumors. | | Definition | ChEBI: A 14beta-hydroxy steroid that is bufan-20,22-dienolide having hydroxy substituents at the 5beta- and 14beta-positions. It has been isolated from the skin of the toad Bufo bufo. | | General Description | Bufalin is a C-24 steroid with an α-pyrone ring positioned at C-17. It is present in the venom glands and skin of toad, Venenum Bufonis. Bufalin is a cardiotonic steroid and is digoxin-like component of Chan Su. | | Hazard | Toxic. | | Biochem/physiol Actions | Bufalin is an anti-metastasis drug, which elicits anti-tumor functionality by favoring cell cycle arrest and apoptosis in various cancer types including hepatocellular, bladder and osteosarcoma. It also promotes autophagic cell death and possesses anti-inflammatory properties. Bufalin is a steroid receptor coactivator (SRC) inhibitor. | | Enzyme inhibitor | This cardioactive C-24 steroid (FW = 386.52 g/mol; CAS 465-21-4; Solubility: 5 mg/mL chloroform, 25 mg/mL DMSO), also named 3,14- dihydroxybufa-20,22-dienolide;5β,20(22)-bufadienolide-3β,14-diol and 3β,14-dihydroxy-5β,20(22)-bufadienolide, is the major digoxin-like immunoreactive component of Chansu, a traditional Chinese medicine prepared from the skin and venom-containing parotid gland of a poisonous toad. Bufalin increases the doubling time of three prostate cancer cell lines, inducing apoptosis and the caspase-3 activity. Expression of other proapoptoptic factors, such as mitochondrial Bax and cytosolic cytochrome c, were also increased. Bufalin also reduces serum-induced invasiveness of human hepatocellular cancer SK-Hep1 cells, markedly inhibiting MMP-2 and MMP-9 activities. It also attenuates phosphoinisitide-3-kinase (PI3K) and AKT phosphorylation was associated with reduced levels of NF- κB. Bufalin also suppresses protein levels of FAK, Rho A, VEGF, MEKK3, MKK7, and uPA. Such observations indicate that bufalin is as an antiinvasive agent that inhibits MMP-2 and -9 and alters PI3K/AKT and NF- κB signaling pathways. |
| | Bufalin Preparation Products And Raw materials |
|